ARROWHEAD PHARMACEUTICALS, INC.
For the period ended Jun 30, 2026. Filed Aug 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 4, 2026
ARWR$49.00-0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive (Loss) Income
(in thousands, except per share amounts)
| Three Months Ended June 30, | Nine Months Ended June 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Revenue | $75,253 | $27,767 | $413,023 | $572,976 |
| Operating expenses: | ||||
| Research and development | 198,223 | 162,368 | 548,679 | 432,472 |
| Selling, general and administrative | 47,123 | 30,949 | 134,888 | 86,264 |
| Total operating expenses | 245,346 | 193,317 | 683,567 | 518,736 |
| Operating (loss) income | (170,093) | (165,550) | (270,544) | 54,240 |
| Other income (expense): | ||||
| Interest income | 16,935 | 11,019 | 43,496 | 28,236 |
| Interest expense | (24,562) | (24,382) | (70,913) | (67,667) |
| Loss on equity method investment | (2,470) | — | (9,190) | — |
| Gain on VIE's sale of IPR&D assets | — | — | 19,000 | — |
| Other, net | 1,285 | (176) | (52) | 603 |
| Total other (expense) income | (8,812) | (13,539) | (17,659) | (38,828) |
| (Loss) income before income tax expense (benefit) and noncontrolling interest | (178,905) | (179,089) | (288,203) | 15,412 |
| Income tax expense (benefit) | 11 | (437) | 46 | 1,419 |
| Net (loss) income including noncontrolling interest | $(178,916) | $(178,652) | $(288,249) | $13,993 |
| Net income (loss) attributable to noncontrolling interest, net of tax | 15,364 | (3,411) | 7,956 | (8,126) |
| Net (loss) income attributable to Arrowhead Pharmaceuticals, Inc. | $(194,280) | $(175,241) | $(296,205) | $22,119 |
| Net (loss) income per share attributable to Arrowhead Pharmaceuticals, Inc.: | ||||
| Basic | $(1.36) | $(1.26) | $(2.10) | $0.17 |
| Diluted | $(1.36) | $(1.26) | $(2.10) | $0.17 |
| Weighted-average shares used in calculating | ||||
| Basic | 143,378 | 139,039 | 141,331 | 132,385 |
| Diluted | 143,378 | 139,039 | 141,331 | 133,352 |
| Comprehensive (loss) income: | ||||
| Net (loss) income including noncontrolling interest | $(178,916) | $(178,652) | $(288,249) | $13,993 |
| Other comprehensive (loss) income, net of tax: | ||||
| Unrealized gains (losses) on available-for-sale securities, net | (2,254) | 876 | (9,042) | 1,022 |
| Foreign currency translation adjustments | 487 | 91 | 1,588 | (415) |
| Total other comprehensive income (loss) | (1,767) | 967 | (7,454) | 607 |
| Comprehensive (loss) income | (180,683) | (177,685) | (295,703) | 14,600 |
| Comprehensive income (loss) attributable to noncontrolling interest | 15,573 | (3,411) | 8,609 | (8,126) |
| Comprehensive (loss) income attributable to Arrowhead Pharmaceuticals, Inc. | $(196,256) | $(174,274) | $(304,312) | $22,726 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.